Based on the Ultragenyx stock forecast from 12 analysts, the average analyst target price for Ultragenyx is USD 90.24 over the next 12 months. Ultragenyx’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Ultragenyx is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, Ultragenyx’s stock price was USD 45.78. Ultragenyx’s stock price has changed by +5.48% over the past week, +7.31% over the past month and -0.24% over the last year.
No recent analyst target price found for Ultragenyx
No recent average analyst rating found for Ultragenyx
Company Overview Ultragenyx
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California. Read Less
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationa...Read More
Frequently Asked Questions About Ultragenyx (RARE) Stock
Based on ratings from 12 analysts Ultragenyx's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 15 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on RARE's stock to indicate if its a good dividend stock.
Based on targets from 12 analysts, the average taret price for RARE is USD 90.24 over the next 12 months. The maximum analyst target price is USD 140 while the minimum anlayst target price is USD 48.
Unfortunately we do not have enough data on RARE's stock to indicate if its overvalued.
The last closing price of RARE's stock was USD 45.78.
The most recent market capitalization for RARE is USD 4.07B.
Based on targets from 12 analysts, the average taret price for RARE is projected at USD 90.24 over the next 12 months.
This means that RARE's stock price may go up by +97.11% over the next 12 months.
We can't find any ETFs which contains Ultragenyx's stock.
As per our most recent records Ultragenyx has 1,276 Employees.
Ultragenyx's registered address is 60 Leveroni Court, Novato, CA, United States, 94949.
You can get more information about it from Ultragenyx's website at https://www.ultragenyx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Ultragenyx (RARE) Stock
Based on ratings from 12 analysts Ultragenyx's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 15 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on RARE's stock to indicate if its a good dividend stock.
Based on targets from 12 analysts, the average taret price for RARE is USD 90.24 over the next 12 months. The maximum analyst target price is USD 140 while the minimum anlayst target price is USD 48.
Unfortunately we do not have enough data on RARE's stock to indicate if its overvalued.
The last closing price of RARE's stock was USD 45.78.
The most recent market capitalization for RARE is USD 4.07B.
Based on targets from 12 analysts, the average taret price for RARE is projected at USD 90.24 over the next 12 months.
This means that RARE's stock price may go up by +97.11% over the next 12 months.
We can't find any ETFs which contains Ultragenyx's stock.
As per our most recent records Ultragenyx has 1,276 Employees.
Ultragenyx's registered address is 60 Leveroni Court, Novato, CA, United States, 94949.
You can get more information about it from Ultragenyx's website at https://www.ultragenyx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for RARE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
